A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs CC 11050 (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Adverse reactions
- Acronyms APHRODITE
- 10 Jun 2017 Biomarkers information updated
- 16 May 2017 Status changed from recruiting to completed.
- 17 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.